利拉鲁肽注射液联合盐酸吡格列酮片治疗2型糖尿病的临床研究

Clinical trial of liraglutide injection combined with pioglitazone hydrochloride tablets in the treatment of type 2 diabetes mellitus

目的观察利拉鲁肽注射液联合盐酸吡格列酮片治疗2型糖尿病的临床疗效及安全性。方法将190例2型糖尿病患者随机分为对照组100例和试验组90例。对照组给予吡格列酮片每次30 mg,qd,于早餐后口服;试验组在对照组治疗的基础上,给予利拉鲁肽每次0.6~1.8 mg,qd,皮下注射。2组患者均治疗12周。比较2组患者的临床疗效、空腹血糖和胰岛素抵抗指数(HOMA-IR),以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为96.67%(87例/90例)和88.00%(88例/100例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的空腹血糖分别为(7.33±1.09)和(8.65±1.08)mmol·L-1,HOMA-IR分别为(6.62±1.13)和(8.81±1.55),差异均有统计学意义(均P<0.05)。2组患者均未发生药物不良反应。结论利拉鲁肽注射液联合盐酸吡格列酮片治疗2型糖尿病的临床疗效确切,其能有效地降低空腹血糖,改善胰岛素抵抗,且安全性较好。

Objective To observe the clinical efficacy and safety of liraglutide injection combined with pioglitazone hydrochloride tablets in the treatment of type 2 diabetes mellitus.Methods A total of 190 patients with type 2 diabetes mellitus were randomly divided into control group(n=100 cases)and treatment group(n=90 cases).Control group was given pioglitazone tablets 30 mg per time,qd,orally after breakfast.Treatment group was given liraglutide 0.6-1.8 mg,qd,subcutaneous injection,on the basis of control group.Two groups were treated for 12 weeks.The clinical efficacy,fasting blood glucose,insulin resistance index(HOMA-IR)and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 96.67%(87 cases/90 cases)and88.00%(88 cases/100 cases)with significant difference(P<0.05).After treatment,the fasting blood glucose of treatment and control groups were(7.33±1.09)and(8.65±1.08)mmol·L-1,HOMA-IR were(6.62±1.13)and(8.81±1.55),the differences were statistically significant(all P<0.05).No adverse drug reactions occurred in two groups.Conclusion Liraglutide injection combined with pioglitazone hydrochloride tablets has a definitive clinical efficacy and safety in thetreatment of type 2 diabetes mellitus,which can effectively reduce fasting blood sugar and improve insulin resistance with high safety.